{
    "clinical_study": {
        "@rank": "121068", 
        "arm_group": [
            {
                "arm_group_label": "Plazomicin in Combination with Meropenem or Tigecycline", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous repeating doses"
            }, 
            {
                "arm_group_label": "Colistin in Combination with Meropenem or Tigecycline", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous repeating doses"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, randomized, open-label superiority study comparing the efficacy and\n      safety of plazomicin with colistin when combined with a second antibiotic (either meropenem\n      or tigecycline) in the treatment of patients with bloodstream infection (BSI) or nosocomial\n      pneumonia due to CRE. Therapeutic drug management (TDM) will be used to help ensure that\n      plazomicin exposures lie within an acceptable range of the target mean steady-state area\n      under the curve (AUC)."
        }, 
        "brief_title": "A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)", 
        "condition": [
            "BSI Due to CRE", 
            "Nosocomial Pneumonia Due to CRE"
        ], 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Principal Inclusion Criteria:\n\n          -  APACHE II score between 15 and 30, inclusive\n\n          -  Presumptive identification of a carbapenem resistant-member of the Enterobacteriaceae\n             as defined by rapid testing methods from an appropriate culture specimen \u2264 72 hours\n             prior to study  OR Definitive identification of a carbapenem resistant-member of the\n             Enterobacteriaceae as defined by local lab identification and susceptibility testing\n             from an appropriate culture specimen \u2264 72 hours prior to study entry\n\n          -  Diagnosis of BSI as defined by at least one positive blood culture meeting the above\n             microbiological criteria associated with at least one of the following signs of\n             infection: Fever or hypothermia; New onset arterial hypotension; Elevated total\n             peripheral white blood cell (WBC) count  > 10,000 cells/mm3, > 15% immature\n             neutrophils (band forms) regardless of total peripheral WBC count, or leukopenia with\n             total WBC count < 4500 cells/mm3\n\n          -  Or, diagnosis of nosocomial pneumonia in a patient on mechanical ventilation, as\n             defined by lower respiratory tract or pleural fluid culture meeting the above defined\n             microbiological criteria, and associated with the following clinical signs of\n             pneumonia: A chest X-ray or computed tomography (CT) scan with findings consistent\n             with a diagnosis of pneumonia; Worsening gas exchange; Purulent deep respiratory\n             specimen; AND one of the following: Elevated total peripheral WBC count > 10,000\n             cells/mm3, > 15% immature neutrophils (band forms) regardless of total peripheral WBC\n             count, or leukopenia with total WBC count < 4500 cells/mm3; Fever or hypothermia\n\n        Principal Exclusion Criteria:\n\n          -  Patient has received more than 72 hours of empirical therapy\n\n          -  Infection with CRE isolate with reduced susceptibility to colistin\n\n          -  Presence of refractory septic shock\n\n          -  Objective clinical evidence for any of the following clinical syndromes that\n             necessitates antimicrobial therapy for greater than 14 days: endovascular infection\n             including endocarditis, osteomyelitis, prosthetic joint infection, meningitis and/or\n             other central nervous system infections\n\n          -  Objective clinical evidence of infectious involvement of intravascular material not\n             intended to be removed within 4 calendar days of initial positive culture\n\n          -  Pulmonary disease that precludes evaluation of therapeutic response including known\n             bronchial obstruction or a history of post-obstructive pneumonia, tracheobronchitis,\n             primary lung cancer or malignancies metastatic to the lung, bronchiectasis, known or\n             suspected active tuberculosis\n\n          -  Patients with severe liver disease (Child-Pugh score of Class C)\n\n          -  Patients in acute renal failure or on intermittent hemodialysis (IHD) at the time of\n             screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970371", 
            "org_study_id": "ACHN-490-007", 
            "secondary_id": [
                "2013-001997-18", 
                "U1111-1151-2686"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Plazomicin in Combination with Meropenem or Tigecycline", 
                "intervention_name": "plazomicin", 
                "intervention_type": "Drug", 
                "other_name": "plazomicin sulfate"
            }, 
            {
                "arm_group_label": "Colistin in Combination with Meropenem or Tigecycline", 
                "intervention_name": "colistin", 
                "intervention_type": "Drug", 
                "other_name": "colistimethate sodium"
            }, 
            {
                "arm_group_label": [
                    "Plazomicin in Combination with Meropenem or Tigecycline", 
                    "Colistin in Combination with Meropenem or Tigecycline"
                ], 
                "description": "Second adjunctive antibiotic therapy (Investigator's choice of either meropenem or tigecycline)", 
                "intervention_name": "meropenem", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Plazomicin in Combination with Meropenem or Tigecycline", 
                    "Colistin in Combination with Meropenem or Tigecycline"
                ], 
                "description": "Second adjunctive antibiotic therapy (Investigator's choice of either meropenem or tigecycline)", 
                "intervention_name": "tigecycline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Colistin", 
                "Meropenem", 
                "Tigecycline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gram-negative", 
            "Bacterial infection"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Englewood", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badajoz", 
                        "country": "Spain"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Greece", 
                "Italy", 
                "Spain", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)", 
        "other_outcome": [
            {
                "measure": "Microbiological response at end of treatment", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Microbiological response at test of cure", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Microbiological response at end of study", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "overall_contact": {
            "email": "clinical-trials@achaogen.com", 
            "last_name": "Clinical Trials Support"
        }, 
        "overall_official": {
            "affiliation": "Achaogen, Inc.", 
            "last_name": "Lynn E Connolly, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "All-cause mortality at 28 days", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970371"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to death through 28 days", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "All-cause mortality at 14 days", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Clinical response (as determined by the adjudication committee) at end of treatment", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Clinical response (as determined by the adjudication committee) at test of cure", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Clinical response (as determined by the adjudication committee) at end of study", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Overall incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Plazomicin PK parameters including AUC0-24,Cmax, and Cmin", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Frequency with which the use of TDM leads to a dose adjustment of plazomicin", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Achaogen, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Health and Human Services", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Achaogen, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}